Melanoma recurrent – Diagnostics – Overview of Information and Clinical Research

Recurrent melanoma refers to melanoma that has returned after initial treatment, despite the best efforts of medical teams. Understanding when to seek testing, what methods are used to detect recurrence, and how patients qualify for clinical trials can help you navigate life after an initial melanoma diagnosis with greater confidence and awareness.

Introduction: Who Should Undergo Diagnostics and When

If you have been treated for melanoma, you are not alone in wondering whether the cancer might come back. Even after successful treatment, some melanoma cells can survive in the body, remaining undetected by standard screening methods. These hidden cells may eventually grow into a new tumor, leading to what doctors call a recurrence. This is why ongoing monitoring is so important for anyone who has had melanoma in the past.^[1]

People who have been diagnosed with melanoma once are at a higher risk of developing another melanoma compared to those who have never had the disease. The cancer can return near the original site where it was first found, or it can appear in a completely different location on the body. In some cases, it may spread to nearby lymph nodes or even to distant organs. This means that regular check-ups and skin examinations become a lifelong part of your health routine.^[6]

The timing and frequency of diagnostic testing depend largely on the original stage of your melanoma. For individuals who had early-stage melanoma, doctors often recommend follow-up visits every six to twelve months. However, if your melanoma was thicker or more advanced, your medical team may suggest more frequent examinations, such as every three to six months, especially in the first few years after treatment. As time passes without signs of recurrence, the intervals between check-ups can gradually become longer.^[6]

Most recurrences happen within the first two to three years after the primary melanoma has been removed. However, melanoma can return even more than ten years after the initial diagnosis, although the risk becomes lower as time goes on. This unpredictable pattern makes it essential to remain vigilant and continue regular skin checks, even if many years have passed since your initial treatment.^[7]

⚠️ Important

Anyone who has been treated for melanoma should attend all scheduled follow-up appointments. Early detection of recurrence is the most important factor in successful treatment. If you notice any new or changing moles, lumps under the skin, or other unusual changes, contact your doctor immediately rather than waiting for your next scheduled visit.

You should seek diagnostic testing if you observe any changes in your skin or overall health. This includes new spots or lesions that appear different from your other moles, any existing moles that begin to change in size, shape, or color, or the development of lumps under the skin or in areas where lymph nodes are located. Additionally, symptoms such as persistent cough, unexplained weight loss, bone pain, or headaches may signal that melanoma has spread to other parts of the body and should prompt immediate medical evaluation.^[7]

Diagnostic Methods for Identifying Recurrent Melanoma

Detecting recurrent melanoma involves a combination of visual examinations, imaging techniques, and tissue sampling. The goal is to find any returning cancer as early as possible, when treatment options are most effective. Your healthcare team will use different methods depending on your individual risk factors and the characteristics of your original melanoma.

Physical and Skin Examinations

The foundation of monitoring for recurrent melanoma is the regular physical examination. During these visits, your doctor or dermatologist will carefully inspect your entire skin surface, looking for any new spots or changes to existing moles. They will pay special attention to the area where your original melanoma was located, checking the surgical scar and surrounding skin for any signs of local recurrence.^[3]

Your doctor will also examine your lymph nodes, which are small bean-shaped organs that are part of your immune system. Melanoma often spreads first to the nearest lymph nodes. By gently feeling the areas where lymph nodes are located, such as in your neck, armpits, and groin, your doctor can detect any unusual swelling or lumps that might indicate the cancer has returned.^[4]

Self-examination is equally important. Between medical appointments, you should check your own skin regularly, ideally once a month. When examining your skin, remember the ABCDE rule, which helps identify potentially concerning moles. A stands for Asymmetry, meaning one half of the mole does not match the other half. B stands for Borders that are irregular or notched. C refers to Color that is uneven or mottled across the mole. D means Diameter larger than the tip of a pencil eraser. E stands for Evolving, indicating that the mole is changing over time in size, shape, or color.^[6]

Imaging Tests

In addition to physical examinations, your doctor may recommend various imaging tests to look for signs of recurrent melanoma inside your body. These tests are particularly important for people who had more advanced melanoma at their initial diagnosis, as they have a higher risk of the cancer spreading to internal organs.

Computed tomography, commonly known as a CT scan, uses X-rays to create detailed cross-sectional images of your body. This test can help detect melanoma that has spread to the chest, abdomen, pelvis, or other internal areas. During a CT scan, you lie on a table that slides through a large, donut-shaped machine. The procedure is painless, though you may be asked to drink a contrast liquid or receive an injection to help certain areas show up more clearly on the images.^[5]

Magnetic resonance imaging, or MRI, uses powerful magnets and radio waves instead of X-rays to produce detailed pictures of the inside of your body. MRI scans are particularly useful for examining the brain and spinal cord, as melanoma can sometimes spread to these areas. The test involves lying still inside a tunnel-like machine for 30 to 60 minutes. Some people feel claustrophobic during the scan, but the medical team can provide support to make you more comfortable.^[5]

Positron emission tomography, known as a PET scan, involves injecting a small amount of radioactive sugar into your bloodstream. Cancer cells, which grow more rapidly than normal cells, absorb more of this sugar and show up as bright spots on the scan images. PET scans are often combined with CT scans to provide both anatomical and metabolic information, helping doctors identify areas where melanoma may have returned or spread.^[5]

Biopsy and Tissue Analysis

If a suspicious area is found during a physical examination or imaging test, your doctor will likely recommend a biopsy. A biopsy involves removing a small sample of tissue so it can be examined under a microscope by a specialist called a pathologist. This is the only way to definitively confirm whether melanoma has recurred.

There are several types of biopsies. A skin biopsy is performed when there is a suspicious spot on the skin. The doctor numbs the area with a local anesthetic and then removes all or part of the lesion. The procedure is usually quick and causes minimal discomfort. If a lump is felt under the skin or in a lymph node, a fine-needle aspiration or core needle biopsy may be performed to collect cells or tissue from that area.^[4]

In some cases, an excisional biopsy or lymph node dissection may be needed. This means surgically removing an entire suspicious lymph node or group of lymph nodes to check for cancer cells. This is more invasive than a needle biopsy but provides more complete information about whether melanoma has spread to the lymphatic system.^[4]

Blood Tests

Currently, there are no standard blood tests that can reliably detect recurrent melanoma on their own. However, your doctor may order blood tests to check your overall health and organ function, especially if melanoma is suspected to have spread to internal organs such as the liver or kidneys. Blood tests can reveal abnormalities in liver enzymes, kidney function, or blood cell counts that might suggest the presence of cancer, although these findings are not specific to melanoma.^[5]

Research is ongoing to develop blood-based tests that can detect melanoma cells or specific markers associated with the disease. If such tests become available in the future, they may offer a less invasive way to monitor for recurrence. However, at present, physical examination, imaging, and biopsy remain the primary diagnostic methods.

Diagnostics for Clinical Trial Qualification

If your melanoma has recurred, your doctor may discuss the possibility of participating in a clinical trial. Clinical trials are research studies that test new treatments or new combinations of existing treatments to see if they are safe and effective. These trials offer access to cutting-edge therapies that are not yet widely available and contribute to medical knowledge that may help future patients.^[13]

To determine whether you are eligible for a specific clinical trial, additional diagnostic tests are often required beyond those used for standard recurrence detection. Each trial has its own set of entry criteria, known as inclusion and exclusion criteria, which define exactly what characteristics participants must have to join the study.

Staging and Disease Extent Assessment

One of the first steps in determining clinical trial eligibility is confirming the stage and extent of your recurrent melanoma. Trials are often designed for patients with specific stages of disease. For example, some trials may focus on locally recurrent melanoma that has returned near the original site, while others may be designed for patients whose melanoma has spread to distant organs.

To accurately stage your recurrence, you may need comprehensive imaging studies, including CT scans, MRI scans, and PET scans. These tests help identify all areas where melanoma cells may be present, ensuring that you are matched with a trial appropriate for your disease status.^[12]

Biomarker Testing

Biomarkers are biological molecules found in your blood, other body fluids, or tissues that can indicate the presence of disease or predict how a disease will behave. In melanoma, certain biomarkers can also help determine whether specific targeted therapies will be effective.

One of the most important biomarkers in melanoma is the BRAF gene. Approximately half of all melanomas have a mutation in the BRAF gene, which causes the cancer cells to grow and divide uncontrollably. Testing for BRAF mutations involves analyzing a sample of your tumor tissue, either from the original melanoma or from the recurrent tumor. If your melanoma has a BRAF mutation, you may be eligible for clinical trials testing BRAF inhibitors or combinations of BRAF and MEK inhibitors, which are drugs specifically designed to target these genetic changes.^[4]

Other genetic mutations, such as those in the NRAS or KIT genes, may also be tested. Knowing the specific genetic profile of your melanoma helps match you to the most appropriate clinical trial and increases the likelihood that the experimental treatment will be effective for you.^[12]

Performance Status Evaluation

Clinical trials typically require participants to have a certain level of physical health and ability to perform daily activities. This is assessed using a performance status scale, such as the Eastern Cooperative Oncology Group (ECOG) scale, which rates your ability to care for yourself, walk, and carry out work or household activities.

Your doctor will evaluate your performance status through a physical examination and by asking questions about your daily functioning. Patients with better performance status are more likely to tolerate experimental treatments and benefit from clinical trial participation.

Laboratory Tests

Before enrolling in a clinical trial, you will usually need a series of laboratory tests to ensure that your organs, especially your liver, kidneys, and bone marrow, are functioning well enough to handle the experimental treatment. These tests typically include:

Complete blood count to measure red blood cells, white blood cells, and platelets
Blood chemistry tests to assess liver and kidney function
Coagulation tests to check how well your blood clots

The results of these tests help the research team determine whether it is safe for you to participate in the trial and whether any dose adjustments might be needed.^[13]

Tumor Biopsy for Research Purposes

Some clinical trials require a fresh biopsy of your recurrent melanoma to collect tissue samples for research. These samples may be used to study how the tumor responds to the experimental treatment at a cellular level, identify additional biomarkers, or better understand the biology of melanoma recurrence. While this involves an additional procedure, it contributes valuable information to the scientific community and may provide insights into your own treatment.^[12]

Previous Treatment History

Your history of previous melanoma treatments is a critical factor in clinical trial eligibility. Trials may be specifically designed for patients whose melanoma has recurred after certain types of therapy, such as immunotherapy or targeted therapy. Your medical team will review your treatment records carefully to determine which trials match your history.

For instance, if your melanoma recurred after you received adjuvant immunotherapy, there may be trials exploring different immunotherapy combinations, alternative immune checkpoint inhibitors, or entirely new classes of drugs. Understanding how your cancer responded to past treatments helps guide the selection of future therapies.^[12]

Prognosis and Survival Rate

Prognosis

The outlook for recurrent melanoma varies significantly based on where and when the cancer returns. The location of recurrence is one of the most important factors influencing prognosis. Melanoma that comes back near the original site, on the surrounding skin, or in nearby lymph nodes generally has a better prognosis than melanoma that has spread to distant organs such as the lungs, liver, brain, or bones.^[4]

The timing of recurrence also matters. Melanomas that recur within the first two to three years after initial treatment tend to be more aggressive, while those that appear many years later may behave less aggressively. However, each case is unique, and advances in treatment, particularly immunotherapy and targeted therapy, have significantly improved outcomes for many patients with recurrent melanoma.^[7]

The stage of your original melanoma at diagnosis influences your risk of recurrence and the likely outcome if the cancer does return. People who had early-stage melanoma initially have a lower risk of recurrence and better prognosis if it does come back. Those diagnosed with thicker melanomas or melanomas that had already spread to lymph nodes have a higher chance of recurrence and may face more challenging disease if it returns.^[6]

Your overall health, age, and how well you tolerate treatment also affect prognosis. Patients who are otherwise healthy and able to receive aggressive treatment may have better outcomes than those with other medical conditions that limit treatment options. Additionally, the response to previous treatments can provide clues about how recurrent melanoma might behave.^[12]

Survival rate

Survival rates for recurrent melanoma are difficult to state precisely because they depend on many individual factors, including the extent of recurrence, the specific treatments received, and personal health characteristics. However, some general patterns have emerged from clinical studies.

For patients with locally recurrent melanoma, meaning the cancer has returned near the original site or in nearby lymph nodes, five-year survival rates can be relatively favorable, especially when the recurrence is detected early and treated promptly with surgery and additional therapies. In contrast, when melanoma recurs as distant metastases, affecting organs far from the original tumor, survival rates are generally lower, though newer treatments have improved outcomes considerably in recent years.^[6]

Importantly, survival statistics are based on large groups of patients and outcomes from past years. They cannot predict exactly what will happen to any individual person. With the advent of effective immunotherapies and targeted therapies over the past decade, many patients with advanced recurrent melanoma are living longer and with better quality of life than was possible in the past. Some patients with stage IV recurrent melanoma can now achieve long-term remission or even cure with these newer treatments.^[6]

#1 Clinical Trials Search in Europe